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An inhalation unit risk factor (URF) was developed for cadmium. The URF is based on excess lung cancer
mortality in a key epidemiological study of cadmium smelter workers (Park et al., 2012). The Park et al.
(2012) study is an update of the Thun et al. (1985) cohort that was previously used to derive a URF in
USEPA (1985). Park et al. re-analyzed the cadmium smelter worker population (near Denver, CO) using
more detailed work history information, a revised cadmium exposure matrix, a detailed retrospective
exposure assessment for arsenic (potential confounder), and updated mortality data (through 2002).
Grouped observed and expected number of lung cancer mortalities along with cumulative cadmium
exposures were used in the current study to obtain the maximum likelihood estimate and asymptotic
variance of the slope (b) for the linear multiplicative relative risk model using Poisson regression
modeling. Life-table analyses were used to derive the ﬁnal URF for cadmium of 4.9E-04 per mg Cd/m3. The
corresponding lifetime air concentration at the 1 in 100,000 no signiﬁcant excess risk level is 0.020 mg
Cd/m3, which can be used to protect the general public in Texas against the potential carcinogenic effects
from chronic exposure to cadmium and cadmium compounds.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 1985, the United States Environmental Protection Agency
(USEPA) classiﬁed cadmium as a probable human carcinogen by
inhalation (Group B1) based on limited evidence of an increase in
lung cancer in humans and sufﬁcient evidence of lung cancer in rats
(USEPA, 1985). In that carcinogenicity assessment, the USEPA
derived an inhalation unit risk factor (URF of 1.8E-03 per mg Cd/m3)
for environmental exposure to cadmium using lung cancer data
from a now outdated occupational study (Thun et al., 1985). More
recently, the International Agency for Research on Cancer (IARC)
classiﬁed cadmium as carcinogenic to humans (Group 1) based on
sufﬁcient evidence for carcinogenicity in both human and animal
studies (IARC, 2012). Similarly, the National Toxicology Program
(NTP) 13th Report on Carcinogens recently classiﬁed cadmium and
compounds as known to be human carcinogens based on sufﬁcient
evidence of carcinogenicity from studies in humans, including
epidemiological and mechanistic studies (NTP, 2014).
Although the USEPA conducted a draft assessment in 1999
(USEPA, 1999), the URF on USEPA's Integrated Risk Information
System (IRIS) has not been updated in three decades (i.e., since
1985). Importantly, a more recent study (Park et al., 2012) isInc. This is an open access article uavailable for doseeresponse assessment of lung cancer mortality in
the Thun et al. cohort of cadmium smelter workers, which was the
basis for USEPA's URF. The Park et al. (2012) study is the latest
update of the Thun et al. (1985) cohort (the previous update was
Stayner et al., 1992). Given the carcinogenic classiﬁcations dis-
cussed above, updated information on the potential carcinogenicity
of cadmium via inhalation is important because cadmium is
detected in ambient air in Texas. Annual averages at ambient air
monitoring sites in Texas range from not detected to 0.003 mg Cd/
m3 (based on speciated PM2.5 or PM10), although nondetects drive
the vast majority of annual site means as well as the statewide
mean of approximately 0.0008 mg Cd/m3 (Texas Air Monitoring
Information System (TAMIS) data for 2005e2014). Thus, it is
important for the Texas Commission on Environmental Quality
(TCEQ) to conduct an updated inhalation carcinogenic assessment
of cadmium based on the latest scientiﬁc data and analyses in order
to develop a URF to help ensure the protection of public health.
Accordingly, a URF for cadmium has been developed based on
doseeresponse analyses of lung cancer mortality data in the key
epidemiological study of Park et al. (2012), the latest update of the
Thun et al. (1985) cohort. The purpose of this paper is to present the
procedures used in the carcinogenic assessment of cadmium and
derivation of the URF. The URF is then used to calculate the envi-
ronmental air concentration associated with the no signiﬁcant
excess risk level of 1 in 100,000 assuming lifetime exposure (TCEQ,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The TCEQ (2015) guidelines for carcinogenic assessment employ
the four-step risk assessment process formalized by the National
Research Council (NRC, 1983, 1994) and the procedures recom-
mended in the most recent USEPA cancer guidelines (e.g., USEPA,
2005) and scientiﬁc literature. For chronic adverse effects deter-
mined or assumed to be associated with linear doseeresponse re-
lationships in the low-dose region, the TCEQ adopts or derives
URFs. That is, for adverse effects associatedwith or assumed to have
a linear doseeresponse at low doses (typically cancer), it is
assumed that an effects threshold does not exist. In such cases, a
linear extrapolation is performed to estimate excess lifetime risk at
lower doses, for example, through use of the calculation of a point
of departure using BEIR IV methodology (NRC, 1988) when data
have been ﬁt to a doseeresponse model. The slope of the line from
zero excess risk at zero exposure to this point of departure is the
inhalation URF, which may be described as the excess risk esti-
mated to result from continuous lifetime exposure to an agent on a
per mg/m3 in air basis (i.e., excess risk per mg/m3 assuming
continuous lifetime exposure).
Human studies are preferred for URF derivation (TCEQ, 2015). In
addition to reviewing the epidemiological studies previously
considered and/or utilized to assess excess lung cancer risk by other
agencies such as the USEPA and OSHA (e.g., Thun et al., 1985;
Stayner et al., 1992 as an update of Thun et al.), a scientiﬁc litera-
ture search was conducted (through November 2015) for more
recent cadmium inhalation epidemiological studies with adequate
data for URF derivation. As with all chemicals for which the TCEQ
develops toxicity factors, external interested parties also had ample
opportunity to submit relevant information (e.g., published, un-
published studies). Park et al. (2012), the latest update of the Thun
et al. (1985) cohort, was identiﬁed as the most appropriate epide-
miological study for inhalation carcinogenic risk assessment as it is
the highest quality epidemiology study of lung cancer risk in
humans exposed to cadmium via inhalation.
Accordingly, the URF is based on excess lung cancer mortality in
Park et al. (2012) as the key epidemiological study. Data from this
cohort of 601 cadmium smelter workers, with 444 deaths including
36 from lung cancer, are considered adequate for a doseeresponse
assessment of cadmium-induced lung carcinogenesis. This cohort
has extensive follow-up (through 2002) and provides standard
mortality ratio (SMR) analyses for lung cancer mortality by cumu-
lative cadmium exposure level. Additional details on the Park et al.
(2012) study and methods utilized for the doseeresponse assess-
ment (e.g., Poisson regression modeling) are provided below.3. Carcinogenic assessment
The following sections discuss key steps in the carcinogenic
assessment of cadmium and development of the URF. Consistent
with Figs. 1e2a of TCEQ (2015), the key steps are generally as
follows:
 Conduct literature review and solicit information from inter-
ested parties.
 Perform carcinogenic weight of evidence (WOE) and mode of
action (MOA) analyses (linear low-dose extrapolation is the
default for a mutagenic or unknown MOA).
 Identify key studies with sufﬁcient information to conduct
doseeresponse analyses (human study data are preferred and
available for cadmium). Conduct doseeresponse modeling with appropriate methods to
derive slope parameter (b) estimates (e.g., linear multiplicative
relative risk model using Poisson regression modeling).
 Develop URF using the best availablemethod (life-table analyses
were used in this case).
The ﬁrst two steps shown above (i.e., literature search, carci-
nogenic WOE andMOA analyses) are inherently part of the process,
but need not be discussed in detail here since the focus of this paper
is on documentation of the doseeresponse analyses and methods
used in the URF derivation process. The ﬁrst step was conducted by
the TCEQ in early December 2015 and did not reveal a study more
appropriate for doseeresponse modeling than the cohort used by
the USEPA (1985), OSHA (1992), and others for the inhalation
carcinogenic assessment of cadmium. Park et al. (2012) is the latest
update for that cohort. In regard to the second step, carcinogenic
WOE analyses have recently been conducted by IARC (2012) and
NTP (2014) and concur that cadmium is carcinogenic to humans via
inhalation. Furthermore, an MOA analysis is beyond the scope of
this paper andwould not likely result in a departure from the linear,
low-dose extrapolation approach employed (e.g., USEPA, 1999 in-
dicates that good doseeresponse data are not available for the
endpoints related to nonlinear mechanisms of cadmium carcino-
genicity; even evaluating the potential for a threshold effect apart
from the MOA, Park et al. indicate that comparing model ﬁt for
cumulative exposures calculated with a threshold in the range
0.01e0.10 mg Cd/m3 provided little support for a threshold effect).
Consequently, the following sections focus on the last three steps
shown above.
3.1. Key study and cancer endpoint
Human epidemiological study data are preferable for the
development of a URF (TCEQ, 2015). Consequently, while both
human and animal data are available for cadmium (ATSDR, 2012),
human epidemiological study data were utilized for an updated
assessment of the carcinogenic potential of cadmium. Although a
number of occupational studies have investigated relationships
between cadmium exposure and cancer, not all epidemiological
studies are adequate to deﬁne doseeresponse relationships. A
cohort of cadmium smelter workers (near Denver, CO) has previ-
ously been identiﬁed as the best basis for the quantitative dos-
eeresponse assessment of lung cancer (e.g., USEPA, 1985, 1999;
OSHA, 1992). The latest update of this cohort, Park et al. (2012):
 Conducted the highest quality epidemiology study of lung
cancer risk in humans exposed to cadmium;
 Used an adequate-sized cohort (n ¼ 601, with 444 deaths rep-
resenting 74%) with 99% ascertainment of vital status;
 Characterized exposure on an individual basis using duration
worked in a given job category and the average exposure level
for that category;
 Observed an exposureeresponse relationship between lung
cancer mortality and cumulative cadmium exposure; and
 Performed analyses to examine potential confounding by con-
current exposure to arsenic.
More speciﬁcally, Park et al. (2012) re-analyzed the cadmium
smelter worker population from Thun et al. (1985) exhibiting
excess lung cancer using more detailed work history information, a
revised cadmium exposure matrix, a detailed retrospective expo-
sure assessment for arsenic, and updated mortality data
(1940e2002). The earlier cadmium exposure assessment was
revised following further analysis of personal protective equipment
(PPE) with PPE protection factors developed using parallel air
Fig. 1. Example of linear approach for low-dose extrapolation.
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Fig. 2. Lung cancer incidence versus mortality.
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exposure matrix consisted of estimated cadmium air concentra-
tions for 32 job activities in six time periods: <1950, 1950e1954,
1955e1959, 1960e1964, 1965e1979, and 1980e2002. For the
arsenic exposure assessment, there were 165 determinations for
airborne arsenic from 44 area and 121 personal samples in the
period 1944e1983. It was assumed that the same PPE protection
factors applied to both cadmium and arsenic exposures. The arsenic
exposure matrix was based on models predicting air concentra-
tions of arsenic from: (1) total dust measurements; (2) feedstock
arsenic levels recorded since 1939; and (3) urinary arsenic mea-
surements. The resulting arsenic exposure matrix speciﬁed yearly
levels from 1939 to 1983 in each of four groups of job activity titles
observed to have similar levels. Arsenic exposure levels prior to
1939 (when feedstock data were not available) were assumed to be
the same as those estimated for 1939 (only 12.5% of the study
population was hired prior to 1939), and those after 1983 were
assumed to be the same as those in 1983. From work histories and
the exposure matrices, an exposure history was compiled for each
worker consisting of his average cadmium and arsenic air con-
centration in each 10-day period since January 1, 1920. Cumulative
exposures were calculated for use in the SMR analyses.
Study results from Park et al. (2012) demonstrate: (1) astatistically signiﬁcant effect of cadmium independent of arsenic
(SMRof 3.2 for 10mg Cd/m3-yr, p¼ 0.012); (2) a substantial healthy
worker effect for lung cancer (SMR of 0.69 for unexposed workers);
and (3) a large deﬁcit in lung cancer mortality among Hispanic
workers (SMR of 0.27, p ¼ 0.009), who are known to have low lung
cancer rates. These ﬁndings support an arsenic-independent effect
for cadmium in risk of lung cancer mortality (i.e., occupational
airborne cadmium is a lung carcinogen independent of arsenic). See
the Park et al. (2012) study for additional information and ﬁndings.
The TCEQ concurs with USEPA (1985, 1999) that this cohort of
cadmium smelter production area workers represents the best
human data upon which to perform a carcinogenic doseeresponse
assessment for URF derivation. A scientiﬁc peer-reviewed literature
search (through November 2015) did not identify a more suitable
epidemiological study for derivation of an inhalation URF for cad-
mium. Thus, Park et al. (2012), the latest update of the Thun et al.
(1985) study, was selected as the key study. Lung cancer mortal-
ity was considered the cancer endpoint of interest for the dos-
eeresponse assessment consistent with the WOE (IARC, 2012; NTP,
2014), the USEPA analyses (1985, 1999), and other cancer risk an-
alyses for cadmium (e.g., OSHA, 1992).3.2. Dose metric and dose-response data
The key occupational study (Park et al., 2012) used for URF
development evaluated lung cancer mortality in white male
workers by the mean cumulative inhalation exposure level for each
of six exposure groups. As is often the case, cumulative inhalation
exposure was lagged 5 years as the most recent exposures may be
etiologically irrelevant to cancer risk because of an apparent min-
imum delay between exposure and the effect of that exposure on
cancer risk. A previous update of this cohort (Stayner et al., 1992)
reported that lagging exposure 5 years increased the magnitude of
the cadmium exposure parameter (b) in Poisson regression analysis
while longer exposure lags decreased both this parameter and the
likelihood of the model. Moreover, Park et al. consider a 5-yr
exposure lag appropriate. SMRs were provided both unadjusted
and adjusted for arsenic exposure and Hispanic ethnicity, since
Hispanics have been reported to have lower lung cancer rates than
non-Hispanics. The doseeresponse data (i.e., cumulative inhalation
exposure and SMR data which will be used to calculate the slope
J. Haney Jr. / Regulatory Toxicology and Pharmacology 77 (2016) 175e183178parameter (b) estimates) from Park et al. (2012) are provided in
Table 1.
As can be seen from examination of Table 1, the total number of
lung cancers in the updated cohort was close to expected (SMRs of
1.12 and 1.06), and lung cancer mortality was statistically increased
only for the highest cumulative inhalation exposure group (mean
cumulative exposure of 33,080 mg Cd/m3-yr) with the SMR of 8.85
unadjusted for arsenic exposure and ethnicity (95% conﬁdence
interval ¼ 1.47, 27.3). However, the 95% conﬁdence interval (1.00,
4.07) for the SMR of 2.19 (unadjusted analysis) at a mean cumula-
tive inhalation exposure of 11,130 mg Cd/m3-yr just barely included
1, and although increased lung cancer did not achieve statistical
signiﬁcance for any other exposure group or overall (SMRs of 1.12
and 1.06), there is an apparent monotonic doseeresponse for
increased lung cancer risk beginning at a mean cumulative expo-
sure of 11,130 mg Cd/m3-yr, and the study did report a statistically
signiﬁcant SMR of 3.2 (p ¼ 0.012) for a cumulative cadmium
exposure of 10,000 mg Cd/m3-yr (independent of arsenic; see
Table 3 of Park et al., 2012). While statistical signiﬁcance as a
measure of strength of the association can be a consideration in the
evaluation of the suitability of epidemiologic study data for dos-
eeresponse modeling, Stayner et al. (1999) note that dos-
eeresponse modeling of weak associations may be informative in
providing potential upper bound or best estimates of risk. Addi-
tionally, lack of statistical signiﬁcance is not proof of lack of effect in
carcinogenicity risk assessments, for the TCEQ to characterize
cancer risk due to cadmium exposure is in the interest of public
health given the carcinogenic classiﬁcations discussed previously,
and there is regulatory agency precedent for use of such studies for
risk characterization (e.g., TCEQ, 2011; USEPA, 1986).3.3. Poisson regression modeling
Poisson regression modeling was used to calculate the
maximum likelihood estimate (MLE) of the slope parameter b for
lung cancer mortality. Maximum likelihood estimation with Pois-
son regression is preferred when the number of responses (i.e.,
observed and expected cases) is known (USEPA, 1986; Crump and
Allen, 1985), as in this case. Two multiplicative relative risk
models were used to calculate b values. The preferred model
included the term “a”, while the other model did not. The “a” term
is used in the preferred model to account for differences in lungTable 1
Lung cancer dose-response data for Park et al. (2012).a
Cumulative exposure (mg Cd/m3-yr) Mean exposureb (mg Cd/m3-yr) Expected lun
Adjusted for arsenic exposure and ethnicity
0e0.72 230 9.091
0.73e2.42 1470 8.511
2.43e7.81 4460 8.889
7.82e16.63 11,130 3.571
16.76e24.98 19,960 1.007
25.15e39.94 33,080 0.224
Total 3000 32.143
Unadjusted for arsenic exposure and ethnicity
0e0.72 230 8.861
0.73e2.42 1470 10.127
2.43e7.81 4460 9.877
7.82e16.63 11,130 3.653
16.76e24.98 19,960 1.186
25.15e39.94 33,080 0.226
Total 3000 33.962
The shaded values are key/critical values as discussed in the text.
a Based on Table 1 of Park et al. (2012).
b Mean 5-yr lagged cumulative exposure (mg/m3-yr) from Table 1 of Park et al. (2012
c Calculated as E ¼ O/SMR.
d 95% conﬁdence interval 1.00, 4.07.
e Statistically signiﬁcant with p < 0.05.cancer mortality background rates between the study population
and the reference population used to determine the number of
expected lung cancer mortalities. The use of this term may account
for potential issues such as the healthy worker effect and any dif-
ferences between internally- and externally-derived background
rates. Incorporation of the “a” term into the relative risk model
equation from USEPA (1986; p. 8e201) yields:
EðOjÞ ¼ a Eoj ð1þ b djÞ
where:
E(Oj) ¼ expected number of lung cancer mortality cases for
exposure group j
a ¼ accounts for differences in lung cancer mortality back-
ground rates between the study population and the reference
population
Eoj ¼ expected number of background lung cancer mortality
cases for exposure group j
b ¼ multiplicative factor by which background risk increases
with cumulative exposure
dj ¼ cumulative exposure for exposure group j
The linear multiplicative relative risk model, as opposed to an
additive risk model, was used to calculate b estimates. The multi-
plicative relative risk model is preferred over the additive risk
model for lung cancer because of more plausible assumptions
concerning the increase in risk with age. For lung cancer, risk in-
creases rapidly with age, which is better captured by the multi-
plicative relative risk model where risk increases over background
rates multiplicatively. By contrast, the additive risk model assumes
that cumulative exposure causes the same absolute increase in risk
regardless of the age at which the risk is calculated, which is less
plausible relative to actual observed age-related increases in lung
cancer incidence and mortality.
For both SMR analyses in Table 1, the mean 5-yr lagged cumu-
lative exposure for each exposure group in units of mg Cd/m3-yr was
used to estimate b values. Additionally, a modeling run was con-
ducted with the “a” term set to 0.8, as Park et al. state that an
intercept of 0.8 is a reasonable choice for the healthy worker effect
in this cohort (e.g., the SMRs for the lowest exposure groups in
Table 1 are 0.77e0.79). Table 2 presents these b estimates for Parkg cancer deaths (E)c Observed lung cancer deaths (O) Lung cancer SMR (O/E)
7 0.77
8 0.94
8 0.90
8 2.24
3 2.98
2 8.93
36 1.12
7 0.79
8 0.79
8 0.81
8 2.19d
3 2.53
2 8.85e
36 1.06
) multiplied by 1000 mg/mg.
Table 2
b Values and Standard Error (SE) Based on Lung Cancer Mortality.
Park et al. (2012) analysis Lag a SE b (95% LCL)a,b b (MLE)a b (95% UCL)a,c
Adjusted for arsenic exposure and ethnicity 5-yr 0.67 1.22E-04 1.41E-05 1.87E-04 3.88E-04
0.80 4.69E-05 5.87E-05 1.36E-04 2.13E-04
e 4.16E-05 1.91E-05 8.76E-05 1.56E-04
Unadjusted for arsenic exposure and ethnicity 5-yr 0.62 1.22E-04 1.78E-05 1.82E-04 3.82E-04
0.80 4.29E-05 4.43E-05 1.15E-04 1.86E-04
e 3.81E-05 9.26E-06 7.20E-05 1.35E-04
The bolded and shaded values are key/critical values as discussed in the text.
a Estimates are excess relative risk per mg Cd/m3-yr.
b 95%LCL ¼ b - (1.645  SE).
c 95%UCL ¼ b þ (1.645  SE).
Table 3
URFs and air concentrations corresponding to 1 in 100,000 excess lung cancer mortality.
Park et al. (2012) analysis Background
rates
Exposure Lag
(a Value)
URF (95% LCL)a air concentration @ 1
in 100,000 excess risk
URF (MLE)a air concentration @ 1
in 100,000 excess risk
URF (95% UCL)a air concentration @ 1
in 100,000 excess risk
Adjusted for arsenic
exposure and ethnicity
TX 5-yr
(0.67)
NA 4.87E-04 per mg/m3
2.05E-02 mg/m3
1.01E-03 per mg/m3
9.89E-03 mg/m3
5-yr
(0.80)
1.53E-04 per mg/m3
6.54E-02 mg/m3
3.54E-04 per mg/m3
2.82E-02 mg/m3
5.55E-04 per mg/m3
1.80E-02 mg/m3
5-yr
(NA)
4.98E-05 per mg/m3
2.01E-01 mg/m3
2.28E-04 per mg/m3
4.38E-02 mg/m3
4.07E-04 per mg/m3
2.46E-02 mg/m3
US 5-yr
(0.67)
NA 5.47E-04 per mg/m3
1.83E-02 mg/m3
1.14E-03 per mg/m3
8.80E-03 mg/m3
5-yr
(0.80)
1.72E-04 per mg/m3
5.82E-02 mg/m3
3.98E-04 per mg/m3
2.51E-02 mg/m3
6.24E-04 per mg/m3
1.60E-02 mg/m3
5-yr
(NA)
5.59E-05 per mg/m3
1.79E-01 mg/m3
2.56E-04 per mg/m3
3.90E-02 mg/m3
4.57E-04 per mg/m3
2.19E-02 mg/m3
Unadjusted for arsenic
exposure and ethnicity
TX 5-yr
(0.62)
NA 4.74E-04 per mg/m3
2.11E-02 mg/m3
9.96E-04 per mg/m3
1.00E-02 mg/m3
5-yr
(0.80)
1.15E-04 per mg/m3
8.66E-02 mg/m3
3.00E-04 per mg/m3
3.34E-02 mg/m3
4.85E-04 per mg/m3
2.06E-02 mg/m3
5-yr
(NA)
2.41E-05 per mg/m3
4.14E-01 mg/m3
1.88E-04 per mg/m3
5.33E-02 mg/m3
3.52E-04 per mg/m3
2.84E-02 mg/m3
US 5-yr
(0.62)
NA 5.33E-04 per mg/m3
1.88E-02 mg/m3
1.12E-03 per mg/m3
8.94E-03 mg/m3
5-yr
(0.80)
1.30E-04 per mg/m3
7.71E-02 mg/m3
3.37E-04 per mg/m3
2.97E-02 mg/m3
5.44E-04 per mg/m3
1.84E-02 mg/m3
5-yr
(NA)
2.71E-05 per mg/m3
3.69E-01 mg/m3
2.11E-04 per mg/m3
4.74E-02 mg/m3
3.95E-04 per mg/m3
2.53E-02 mg/m3
The bolded and shaded values are key/critical values as discussed in the text.
NA ¼ not applicable (i.e., an “a” term was not included in the model or the 95%LCL b value was negative, suggesting zero excess risk is possible, so calculation of an air
concentration at 1 in 100,000 excess risk was not possible.
a Calculated air concentrations at 1 in 100,000 excess risk using the unrounded URF shown (i.e., 0.00001/URF).
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m3-yr.
Consistent with USEPA (2005) and TCEQ (2015) guidelines, in
addition to the b (MLE), the standard error (SE), 95% lower conﬁ-
dence limit on the b (95%LCL b), and 95% upper conﬁdence limit on
the b (95%UCL b) were also calculated and are presented. The 95%
LCL values are negative for the preferred and most conservative
model (which includes the modeled “a” term), suggesting the
possibility of zero excess lung cancer risk with cadmium exposure.3.4. Dosimetric adjustments
Consistent with TCEQ (2015), occupational concentrations
(ConcentrationOC) were converted to environmental concentra-
tions for the general population (ConcentrationHEC) using the
following equation:
ConcentrationHEC ¼ ConcentrationOC  ðVEho=VEhÞ
 ðds per weekoc=ds per weekresÞ
where:ConcentrationHEC ¼ human equivalent concentration for the
general public (mg/m3)
ConcentrationOC ¼ occupational exposure concentration (mg/
m3)
VEho ¼ occupational ventilation rate for an 8-h d (10 m3/d)
VEh ¼ non-occupational/environmental ventilation rate for a
24-h d (20 m3/d)
ds per weekoc ¼ occupational weekly exposure frequency (5
days per week)
ds per weekres ¼ residential weekly exposure frequency (7 days
per week)3.5. URFs and air concentrations at the 1 in 100,000 excess risk
level
URFs express cancer potency in units of excess risk per air
concentration (e.g., excess risk per mg/m3) assuming continuous
lifetime exposure. They are calculated using linear low-dose
extrapolation when the carcinogenic MOA is mutagenic, un-
known, or sufﬁcient information to justify an alternative
Table 5
Texas-speciﬁc and US survival rates.
2011 US all life tablesa 2013 Total Texas population
life tablesb
Age Survival Age Survival
0 1 0 1
1 0.99394 1 0.99418
5 0.99289 5 0.99307
10 0.99230 10 0.99244
15 0.99159 15 0.99176
20 0.98917 20 0.98948
25 0.98493 25 0.98536
30 0.98017 30 0.98075
35 0.97465 35 0.97545
40 0.96784 40 0.96899
45 0.95816 45 0.95971
50 0.94281 50 0.94482
55 0.91975 55 0.92151
60 0.88746 60 0.88732
65 0.84368 65 0.84132
70 0.78184 70 0.77921
75 0.69513 75þ 0.69288
80 0.57493
85 0.41733
a Arias (2015).
b TDSHS (2015).
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several mechanisms have been identiﬁed that potentially
contribute to cadmium-induced carcinogenesis with direct binding
to DNA appearing to be of minor importance (IARC, 2012), the
various molecular mechanisms involved in cadmium-induced
carcinogenesis are poorly understood and are only now begin-
ning to be elucidated (Luevano and Damodaran, 2014). Thus, a clear
picture of the MOA for cadmium-induced lung carcinogenesis is yet
to be elucidated, and default linear low-dose extrapolation is uti-
lized to derive the URF estimates herein.
When a doseeresponse curve is modeled for tumor data, the
URF is the slope of a straight line from the POD to the origin (Fig. 1).
Frequently in animal-based risk estimates, the lower statistical
bounds on the concentration producing a 10% excess tumor
response (LEC10) is used as the POD for linear low-dose extrapo-
lation and calculation of the URF since the limit of detection of
tumor studies is often around 10%, and the resulting equation is:
URF ¼ risk per mg=m3
¼ 0:10=LEC10

where LEC10 is expressed in mg=m
3

However, for this cancer assessment, the response data are
based on humans and have already been ﬁt to a linear equation
(linear multiplicative relative risk model) for use with the BEIR IV
methodology (NRC, 1988).
Table 3 shows URFs and extrapolated air concentrations corre-
sponding to an excess cancer risk of 1 in 100,000 based on b (MLE),
b (95% LCLs), and b (95% UCLs) values from Table 2, which were
calculated based on Park et al. (2012) using maximum likelihood
estimationwith Poisson regression. Air concentrations are based on
extra risk (as opposed to added risk) and a lifetime exposure of 70
years, the default used by TCEQ for exposure analysis (TCEQ, 2015),
and were solved iteratively with life-table analyses using the BEIR
IV approach (NRC, 1988). The following lung cancer mortality rates
and survival probabilities were used in the primary (Texas rates)
and supplementary (US rates) analyses:
 Texas-speciﬁc lung cancer mortality rates for 2008e2012 and
Texas-speciﬁc survival rates for 2013 are the latest available
(Tables 4 and 5); andTable 4
Texas-speciﬁc and US lung cancer mortality rates.
Years US total population 2008e2012
Total lung cancer mortality rates per 100,000
00 0
01e04 0
05e09 0
10e14 0
15e19 0
20e24 0.1
25e29 0.2
30e34 0.5
35e39 1.5
40e44 5.1
45e49 16.6
50e54 36.9
55e59 64.4
60e64 109.9
65e69 186.8
70e74 266.2
75e79 336.6
80e84 375.5
85þ 327.6
a SEER (2015).
b TDSHS (2015). US lung cancer mortality rates for 2008e2012 and US survival
rates for 2011 are the latest available (Tables 4 and 5).
For comparison to results obtained with Texas rates, the similar
results using US rates are also provided in Table 3.
This table provides several candidate URFs to consider. In
selecting a URF, it is noted that lung cancer mortality is reasonably
predictive of lung cancer incidence (i.e., 5-yr survival is only about
17% (American Cancer Society, 2015)) (Fig. 2). Therefore, if inci-
dence data were available, the lung cancer potency estimates
would be expected to be very similar to those derived based on lung
cancer mortality. In such instances, the TCEQ selects a URF (MLE) as
the best estimate of cancer potency (e.g., TCEQ, 2011, 2012, 2014).
USEPA also selected the URF (MLE) as the best estimate for their
URF since the 95%UCL represented “an unnecessary added level ofTexas statewide population 2008e2012
a Total lung cancer mortality rates per 100,000b
0.1
0
0
0
0.1
0.1
0.2
0.5
1.1
3.5
12
31.2
56.8
97.9
172.2
247.5
317.3
348.4
323.2
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tality rates and survival probabilities are preferred. Lastly, the Park
et al. (2012) analysis that adjusted for arsenic exposure and
ethnicity is preferred since, for example, study authors report that
previous associations between cadmium exposure and lung cancer
were confounded by arsenic. This analysis also happens to result in
a slightly higher ﬁnal URF (MLE), as does the analysis where the “a”
term value (0.67) was modeled (compared to results from the
model where the “a” termvaluewas set to 0.8 or themodel without
this term). Therefore, based on the preferred analysis and model,
the ﬁnal URF is 4.9E-04 per mg Cd/m3 (rounded to two signiﬁcant
ﬁgures). Based on this URF, the air concentration corresponding to
the no signiﬁcant excess risk level of 1 in 100,000 is 0.020 mg Cd/m3
when rounded to two signiﬁcant ﬁgures (i.e., 0.00001/4.9E-04 per
mg Cd/m3). Using US lung cancer mortality and survival rates would
result in a very similar URF (5.5E-04 per mg Cd/m3) and air con-
centration at a 1 in 100,000 excess risk (0.018 mg Cd/m3) (Table 3).4. Discussion and conclusions
The ﬁnal URF derived herein (4.9E-04 per mg Cd/m3) was based
on doseeresponse analyses of extra lung cancer risk in a key
epidemiological study cohort of cadmium smelter workers (Park
et al., 2012). Grouped observed and expected number of lung
cancer mortalities along with cumulative cadmium exposures were
used to obtain the MLE and asymptotic variance of the slope (b) for
the linear multiplicative relative risk model using Poisson regres-
sion modeling, and then a life-table analysis was used to derive the
URF. This URF represents an important update to the 1985 assess-
ment by USEPA (USEPA,1985), which was based on a study that had
only followed vital status in the cadmium worker cohort through
1978 (Thun et al., 1985). The URF is based on the latest update of
this cohort (Park et al., 2012) with an additional 24 years of follow-
up (through 2002) to more completely and accurately ascertain the
lung cancer mortality experience of these cadmium production
workers. Up-to-date toxicity factors are important for regulatory
agencies to be able to more accurately assess risk, promote risk
communication with the public based on the latest scientiﬁc in-
formation and assessments, and make the most scientiﬁcally-
defensible decisions possible. As an example speciﬁc to cadmium,
the Oregon Health Authority (OHA) is currently working with the
Oregon Department of Environmental Quality and Multnomah
County Health Department to investigate and evaluate elevated
ambient air concentrations of cadmium (and arsenic) found in
preliminary monitoring in Portland and inform the community
about potential health risks (OHA, 2016). The updated URF based on
US rates (5.5E-04 per mg Cd/m3) can help foster evaluation of long-
term cadmium air data in Portland and elsewhere in the US with
the most recent and scientiﬁcally-defensible URF available.
Based on the URF derived using Texas-speciﬁc rates (4.9E-04 per
mg Cd/m3), the air concentration corresponding to the no signiﬁcant
excess risk level of 1 in 100,000 is 0.020 mg Cd/m3. By comparison,
annual averages at ambient air monitoring sites in Texas are well
below this air concentration for de minimis excess risk and range
from not detected to 0.003 mg Cd/m3, with nondetects driving the
vast majority of annual site means as well as the statewide mean of
approximately 0.0008 mg Cd/m3 (TAMIS data for 2005e2014). In
conclusion, this updated URF (4.9E-04 per mg Cd/m3) is based on
current doseeresponse analyses, may be utilized in the evaluation
of long-term (e.g., lifetime) air concentrations for cadmium and
cadmium compounds, and is considered sufﬁciently health-
protective for use in protecting the general public in Texas against
the potential carcinogenic effects of chronic exposure to cadmium
in ambient air.5. Uncertainty
Many of the areas of uncertainty discussed below are common
to doseeresponse assessments utilizing epidemiological studies.
5.1. Dose-response modeling
The ﬁnal URF is based on the best estimate of the slope b
parameter from the Poisson regression model ﬁt to the most
appropriate available epidemiological data of workers exposed to
cadmium (Park et al., 2012), which represent updated data for the
same cohort used by the USEPA for URF derivation (Thun et al.,
1985). Maximum likelihood estimation with Poisson regression
was used and is preferred when the number of responses (i.e.,
observed and expected cases) is known, as in this case. The
preferred multiplicative relative risk model used to calculate the b
value included a term (a) to account for differences in lung cancer
mortality background rates between the study population and the
reference population used to determine the number of expected
lung cancer mortalities. The use of this term may account for po-
tential issues such as the healthy worker effect and any differences
between internally- and externally-derived background rates. This
represents the best statistical analysis by the TCEQ for the given
epidemiological data so as not to increase the uncertainty and
variability already present in the data. The excess risk of lung cancer
mortality associatedwith a given lifetimemean air concentration of
cadmium would be approximately 2-fold higher if the highest URF
(95% UCL) value based on Texas background rates were predictive
(instead of the MLE) (Table 3), and could be as low as zero if the b
(95% LCL) value were predictive (Table 2).
Conservatively, 5-yr lagged cumulative exposure was used as
the dose metric. This increases the magnitude of the cadmium
exposure parameter (b) in Poisson regression analysis compared to
non-lagged exposure, and was considered appropriate by Park et al.
(2012). Use of this dose metric is common since the most recent
exposures may be etiologically irrelevant to cancer risk because of
an apparent minimum delay between exposure and the effect of
that exposure on cancer risk.
URFs calculated with slope b parameter estimates correspond-
ing to the MLE and 95% UCL were reported for the preferred model
(which includes the modeled “a” term) and analysis (incorporating
adjustments for arsenic exposure and ethnicity) in order to provide
information on the uncertainty in excess risk. The ratio of the URF
(95% UCL) to the preferred best estimate URF (MLE) of 4.9E-04 per
mg/m3was approximately 2.1 (Table 3), indicative of the precision of
the estimates. Additionally, this ﬁnal URF (MLE) is the most con-
servative (i.e., highest) among the six URF (MLE) values calculated
using Texas rates. For example it is 2.1-fold higher (i.e., more con-
servative) than that based on the same analysis (with adjustments
for arsenic exposure and ethnicity) using the multiplicative relative
risk model without the “a” term (Table 3). It is important to also
note that lung cancer was only statistically increased for one
exposure group and was not statistically elevated overall (see SMRs
of 1.06 and1.12 in Table 1), and that the negative b (95% LCL) value in
Table 2 using the preferred multiplicative relative risk model
(which includes the modeled “a” term) and analysis (incorporating
adjustments for arsenic exposure and ethnicity) suggests that risk
could be as low as zero.
5.2. Estimating risks for the general population from occupational
workers
Human studies are preferred over animal studies to develop
toxicity factors for chemicals to avoid uncertainty due to inter-
species differences. However, as in the current case, human
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themselves are subject to the following inherent uncertainties:
 The relationship between lung cancer mortality and exposure to
cadmium was evaluated based on presumably healthy male
workers employed in a cadmium smelter. The model may un-
derestimate excess risks for subpopulations that are particularly
more sensitive to cadmium exposures than cadmium smelter
workers. Although workers are often healthier than the general
population, the approach used by the TCEQ estimates how the
risk of lung cancer changes with exposure to cadmium while
adjusting for the differences between the worker and the gen-
eral population background lung cancer rates (i.e., Texas general
population lung cancer mortality background rates were used as
opposed to those for the workers). Accordingly, the estimates of
excess risk based on the derived models apply to the target
population whose background lung cancer rates and survival
probabilities are used in the estimation of the extra risks (e.g.,
Texas all sexes and all races).
 The general population does not have the same exposure levels
as occupational workers, who are generally exposed to signiﬁ-
cantly higher concentrations. For example, workers were typi-
cally exposed to hundreds of mg Cd/m3 (see Table 1 of Thun et al.,
1985), while the approximate statewide mean is only 0.0008 mg
Cd/m3 (2005e2014).
Lastly, cadmium enters production principally as cadmium ox-
ide dust (agglomerated fume; Thun et al., 1985) and the fact that
absorption of cadmium from the lungs depends on the chemical
nature of the particles deposited (e.g., absorption is around 50% for
cadmium oxide but considerably less for insoluble salts such as
cadmium sulﬁde; WHO, 2000) suggests the potential for greater
toxicity by the relatively more soluble cadmium compounds (e.g.,
cadmium chloride, cadmium oxide fume, cadmium carbonate).
However, cadmium toxicity does not strictly correlate with solu-
bility (e.g., Glaser et al., 1986; ATSDR, 2012). The solubilized cad-
mium ion has been assumed to be responsible for the observed
carcinogenicity of cadmium, with its release from the compound
being governed by the rate of dissolution, the biological half-life/
time in the lung, and the mechanism of clearance (OSHA, 1992).
While the dissolution rate of the cadmium ion is a function of the
solubility of the cadmium compound in the physiological envi-
ronment, particle size determines depositionwithin the respiratory
tract and therefore mechanism of clearance (e.g., mucociliary
escalator, direct uptake by macrophage, dissolution/diffusion), and
biological half-life/time is a function of the efﬁciency of clearance
processes. In this regard, any cytotoxicity that reduces ciliary
movement or overburdens macrophage would increase retention
time, allowing more dissolution and cadmium ion formation than
may be expected based on solubility alone (OSHA, 1992). Because
the carcinogenic potential of a cadmium compound is assumed to
be related to the cumulative amount of cadmium ion released to
target lung cells over time and solubility plays a role, it is noted that
cadmium workers were exposed to cadmium oxide and that cad-
mium is emitted into the atmosphere predominantly as cadmium
oxide and elemental cadmium, which once in the air is rapidly
oxidized to cadmium oxide (Thun et al., 1985; WHO, 2000).
5.3. Uncertainty due to potential exposure estimation error
Results from epidemiology studies have uncertainties because
of potential exposure estimation error or insufﬁcient character-
ization of exposure data (e.g., range, peak, mean exposure levels).
For example, while daily measurements from personal air samples
for each cohort member would be ideal, epidemiologists mustestimate exposure based on professional judgment and whatever
exposure data are available (e.g., area and personal exposure air
measurement data, urinary cadmium and arsenic data, information
on PPE, total dust and feedstock data). As is frequently the case, this
was the case for the key study used for carcinogenic doseeresponse
assessment (Park et al., 2012). For example, air sampling data were
used in parallel with urinary cadmium data to evaluate the pro-
tection factors for PPE (i.e., respirators). Since the exposure matrix
was based on PPE-adjusted air concentrations, the estimated air
concentration for a given job activity may not always accurately
represent that for a particular individual, and dietary intake of
cadmium is variable and makes some contribution to urinary
cadmium even when occupational cadmium exposure is signiﬁ-
cant, this is an area of uncertainty. See Park et al. (2012) for addi-
tional information on the detailed exposure assessment. If
historical exposures were of lessor magnitude than concentration
estimates used to derive the URF, cadmium risk would tend to be
underestimated. Conversely, if historical exposures were of greater
magnitude than concentration estimates used to derive the URF for
this study, excess risk due to cadmium exposure would tend to be
overestimated. Additionally, co-exposure to other carcinogens (e.g.,
arsenic) not adequately accounted for in the doseeresponse
modeling would also tend to result in the overestimation of cad-
mium risk, and this possibility is discussed below.
5.4. Uncertainty due to co-exposures to other compounds
Excess lung cancer risk estimates can be confounded by smok-
ing, which is common in epidemiological studies (i.e., many of the
workers in such studies were smokers). However, both the prior
update of this cohort (Stayner et al., 1992) and OSHA (1992) have
previously examined this potential issue. Smoking habits would
have to vary appreciably between the exposure categories to
confound the relationship between cadmium and lung cancer,
which was considered unlikely by Stayner et al. Additionally,
Stayner et al. (1992) included a parameter for Hispanic ethnicity in
their regression models as a surrogate for lower cigarette smoking
(based on smoking statistics), which had little effect on cadmium
exposure coefﬁcients suggesting that smoking was not a strong
confounder. OSHA (1992) also addressed the potential for con-
founding by smoking in this cohort and indicated that smoking
information was available for 43% of the workers, and that these
data do not suggest that differences in smoking habits (i.e., excess
smoking in the cohort) could have accounted for the excess lung
cancers observed. Thus, based on available information, it appears
unlikely that confounding by cigarette smoking was signiﬁcant.
In regard to other co-exposures, it is noted that the facility had
been an arsenic smelter from 1918 to 1925, and that a previous
nested case-control analysis concluded that arsenic exposure and
cigarette smoking were the major determinants of lung cancer risk
for this cohort (Lamm et al., 1992, 1994). As some arsenic is evolved
during the cadmium recovery process (Stayner et al., 1992; Thun
et al., 1985), it is possible that the URF could reﬂect some contri-
bution of arsenic exposure in addition to that of cadmium. For
example, the geometric mean of arsenic in facility feed material
was estimated to be 2e3% during 1926e1940 (reaching 5e7% four
years within this period), dropping to 1% afterwards (Stayner et al.,
1992), and Thun et al. (1985) estimated an inhaled average of 14 mg
arsenic/m3 based on urinary arsenic levels for workers in the high-
arsenic work areas (i.e., near the roasting and calcine furnaces).
However, OSHA (1992) previously evaluated this potential issue
and: (1) identiﬁed several issues with the work of Lamm et al. (e.g.,
estimates of arsenic exposure and arsenic content of the ﬁnes used
as feedstock before/after 1940); (2) highlighted results of analyses
conducted by Stayner et al. and Thun et al. that are inconsistent
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for the increased lung cancer mortality observed for the cohort
(e.g., the estimated b for cadmium exposure increased rather than
deceased when year of hire was used by Stayner et al. as a proxy for
arsenic exposure); (3) estimated that out of the 24 lung cancer
deaths observed for the cohort as of 1984, nomore than 1was likely
related to arsenic exposure (i.e., 0.97 based on the highest OSHA
estimate of average arsenic exposure, and 0.52 based on the
preferred estimate); and (4) concluded that the excess lung cancer
mortality for this cohort is unlikely to be due to arsenic exposure or
cigarette smoking and is more likely due to cadmium exposure.
More recently, in order to differentiate the effects of cadmium
and arsenic on lung cancer risk, the Park et al. (2012) update of this
cohort conducted a detailed retrospective exposure assessment for
arsenic as had previously been performed for cadmium (e.g., mean
exposure for cadmium was over ten times that for arsenic). Then,
using prior estimates for the exposure-response for arsenic and
lung cancer, the independent effect of cadmium was estimated.
More speciﬁcally, in order to separate the independent contribu-
tions of the correlated exposures for cadmium and arsenic, models
were ﬁt in which the arsenic-associated lung cancer risk was
imposed using exposure-response estimates from previous studies
(as a form of indirect adjustment for a confounder). Attributable
lung cancer cases were calculated by applying the ﬁnal constrained
lung cancer rate model to the observation time of the study pop-
ulation alternately setting cadmium, arsenic, or neither metric to
zero and then computing the predicted number of lung cancer
deaths. Following this procedure in strata of cumulative cadmium
exposure and then taking differences yielded estimated attribut-
able lung cancer cases. Fourteen of the 36 total lung cancer deaths
observed for the cohort (followed through 2002) were predicted to
be attributable to cadmium exposure, while only ﬁve were pre-
dicted to be attributable to arsenic exposure. Most of the arsenic-
attributed deaths occurred in the four lower strata of cadmium
cumulative exposure. Moreover, for the three exposure groups with
an SMR >1, approximately 5e12 times more cases were predicted
to be attributable to cadmium compared to arsenic (see Table 1 of
Park et al., 2012). Park et al. concluded that doseeresponse analyses
with the arsenic effect imposed using prior arsenic exposure-
response estimates should largely remove mutual confounding
between cadmium and arsenic exposures, and the TCEQ relied on
such an analysis (adjusted for arsenic exposure) for derivation of
the URF. Thus, the ﬁnal URF for cadmium (4.9E-04 per mg Cd/m3) is
considered unlikely to be signiﬁcantly affected by worker co-
exposure to arsenic.
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